Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-31

That was the guidance some time back but in the few months they have pushed it back. Continual delays in recruiting patients I believe. Not their fault but it is what it is and offer happens in these trials as we all know. Most recent guidance including today's announcement is as follows:


Long trials, double blinded with patient data still being collected as late as march 2023. Analysis will be significant but hopefully much quicker than 2018. It took over a year from final recruitment for the last HIV trial before basic results were released. I expect they will be quicker this time so their guidance looks about right given the last recruitment dates. Hopefully the "recently developed novel diagnostic assay" is not a bottleneck this time.